Ankylosing Spondylitis Clinical Trials

Ankylosing spondylitis clinical trials test medicines that target specific parts of the immune system driving joint inflammation, along with physical therapy approaches and ways to catch the disease earlier, before permanent spinal changes set in. Many trials measure success using standardized pain and mobility scores tracked over months.

Before biologic medicines existed, treatment options for ankylosing spondylitis were largely limited to pain relievers and physical therapy, neither of which addressed the underlying immune inflammation. Trials of anti-inflammatory biologics changed that, and a newer generation of medicines targeting a different immune signal is expanding options further, particularly for people who don't respond to the first type tried.

Eligibility usually depends on how long you've had symptoms, which joints are affected, and whether you carry a specific genetic marker linked to the disease. Some trials focus on people newly diagnosed, while others specifically recruit those who haven't responded well to standard biologic treatment. Eligibility always varies by study.

Trials generally fall into a few groups. Some test biologics that block a signaling protein called TNF, the first class developed for this disease. Others test newer biologics that block a different signal, interleukin-17, often used when the first type doesn't work well enough. A smaller group studies non-drug approaches, like structured exercise programs, alongside medication.

There's a strong genetic link. Most people with ankylosing spondylitis of European or Chinese background carry a gene marker called HLA-B27, and having a close relative with the condition raises your own risk. That said, most people who carry the HLA-B27 marker never develop ankylosing spondylitis, so genetics alone don't determine who gets it.

Yes, for a meaningful number of people. Ankylosing spondylitis can occur alongside eye inflammation, psoriasis, or inflammatory bowel diseases like Crohn's disease and ulcerative colitis, since all of these conditions belong to a related family of inflammatory diseases. Mentioning any of these to your rheumatologist helps build a complete picture of your case.

Some studies offer compensation for time and travel, and study related care is typically provided at no cost to participants. Compensation varies by trial and is always described during the informed consent process before you agree to anything.

Curious whether clinical trials pay participants? Here's how compensation actually works.

How Much do Clinical Trials Pay? Everything You Need to Know About Getting Paid For Clinical Trials